Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Coley Pharmaceutical Group, Inc. (COLY) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/04/2008 8-K Quarterly results
11/20/2007 8-K/A Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer Inc., Corvette Acquisition Corp., and Coley Pharmaceutical Group, Inc"
11/16/2007 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer, Coley Acquisition Corp., and Coley Pharmaceutical Group, Inc",
"Amendment No. 1, to the Stockholder Rights Agreement, between Coley and Computershare Trust Company, N.A",
"PFIZER TO ACQUIRE COLEY PHARMACEUTICAL GROUP - - -",
"Letter to Employees of Coley"
11/01/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter and Nine-month Financial Results"
10/09/2007 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Other Events, Financial Sta...
Docs: "Stockholder Rights Agreement between the Company and Computershare Trust Company, N.A., which includes as Exhibit A, the Summary of Rights to Purchase Common Stock and as Exhibit B, the Form of Rights Certificate",
"Coley Pharmaceutical Group Adopts Shareholder Rights Plan Wellesley, MA, October 8, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, announced today that its Board of Directors has adopted a Stockholder Rights Plan that is designed to strengthen the ability of the Board of Directors to protect Coley's stockholders. The plan was not adopted in response to any unsolicited offer or takeover attempt. Each stockholder of record of the Company on October 15, 2007, will receive a dividend of one Right for each outstanding share of Common Stock held. Each Right represents the right to purchase, under certain circumstances, one one-hundredth of a share of a new series of preferred stock of t..."
08/02/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Second Quarter and Six-month Financial Results Wellesley, MA, August 2, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the second quarter and six months ended June 30, 2007. FINANCIAL UPDATES"
06/29/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV™"
06/22/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer"
06/15/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Amended and Restated 2005 Stock Plan"
06/11/2007 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Coley Pharmaceutical Group Broadens Leading Toll-like Receptor Platform Through Strategic Acquisition of 3M Company's TLR Therapeutic Research and Development Programs"
05/03/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports First Quarter Financial Results Wellesley, MA, May 3, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the first quarter of 2007. FINANCIAL UPDATES"
04/17/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Licenses VaxImmune™ to Merck for Use in Vaccine Programs"
02/15/2007 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2006 Financial Results Wellesley, MA, February 15, 2007 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported financial results for the fourth quarter and year ended December 31, 2006. The company also announced its annual corporate objectives and provided full-year 2007 financial guidance."
01/22/2007 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Financial Statements and Exh...
Docs: "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy"
12/26/2006 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
12/12/2006 8-K Entry into a Material Definitive Agreement
12/08/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Amends Strategic Alliance License Agreement with GlaxoSmithKline for VaxImmune™ Vaccine Adjuvant"
11/02/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter and Nine-month Financial and Operational Results Wellesley, MA, November 2, 2006 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2006."
08/09/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Second Quarter and Six-month Financial and Operational Results Wellesley, MA, August 9, 2006 - Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the second quarter and six months ended June 30, 2006."
05/17/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley's ACTILON™ for Chronic Hepatitis C Virus Therapy Granted Fast Track Designation from U.S. Food and Drug Administration"
05/11/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports First Quarter Financial Results"
05/01/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Announces Data from Clinical Study of ACTILON™ for Hepatitis C"
04/26/2006 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
02/23/2006 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2005 Financial Results Wellesley, MA, February 23, 2006—Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics™, today reported its financial results for the quarter and year ended December 31, 2005. The Company also provided full year 2006 financial guidance.",
"Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon™ for Hepatitis C"
01/23/2006 8-K Entry into a Material Definitive Agreement
11/29/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Announces Commencement of Phase III Clinical Trials of PF-3512676 for Advanced NSCLC"
11/16/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Actilon™, Coley Pharmaceutical Group's Drug Candidate for Hepatitis C, Demonstrates Anti-Viral Activity in Early Clinical Evaluation"
11/14/2005 8-K Quarterly results
Docs: "Coley Pharmaceutical Group Reports Third Quarter Financial Results Wellesley, MA, November 10, 2005—Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics ™ , today reported its financial results for the third quarter ended September 30, 2005. The company reported revenue of $4.9 million for the third quarter compared to $2.1 million for the same period last year. This increase was primarily due to revenue recognized under Coley's licensing agreement with Pfizer Inc., which was entered into earlier in 2005. Coley reported a net loss attributable to common shareholders for the third quarter of 2005 of $10.8 million versus $9.8 million for the third quarter of 2004. Research and development expenses..."
09/27/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "Coley Pharmaceutical Group Initiates Second Phase Ib Clinical Study of Actilon™ for Treatment of HCV"
08/18/2005 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy